Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Systemic lupus erythematosus

Shifting the SLE management paradigm: challenges and implications

Nature Reviews Rheumatology volume 20, pages 5–6 (2024)Cite this article

Subjects

Newly published European guidelines for the management of systemic lupus erythematosus (SLE) and lupus nephritis, specifically recommending early and aggressive use of new medications, signal that the old paradigm of SLE management is shifting. Although it presents challenges, this shift is welcome — and is likely to have far-reaching implications.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The paradigm shift in SLE management.

References

  1. Fanouriakis, A. et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann. Rheum. Dis. https://doi.org/10.1136/ard-2023-224762 (2023).

    Article  PubMed  Google Scholar 

  2. Fanouriakis, A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 78, 736–745 (2019).

    Article  CAS  PubMed  Google Scholar 

  3. Fanouriakis, A. et al. 2019 update of the joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis. Ann. Rheum. Dis. 79, 713–723 (2020).

    Article  CAS  PubMed  Google Scholar 

  4. United States Food and Drug Administration. BENLYSTA (belimumab) label. FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125370s016lbl.pdf (2012).

  5. United States Food and Drug Administration. SAPHNELO (anifrolumab-fnia) injection label. FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761123s000lbl.pdf (2021).

  6. Kuhn, T.S. The Structure of Scientific Revolutions (Univ. Chicago Press, 1962).

  7. Buie, J. et al. Disparities in lupus and the role of social determinants of health: current state of knowledge and directions for future research. ACR Open Rheumatol. https://doi.org/10.1002/acr2.11590 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Barber, M. R. W. et al. Global epidemiology of systemic lupus erythematosus: narrowing the knowledge gaps. Rheumatology (Oxford) 62, i4–i9 (2023).

    Article  PubMed  Google Scholar 

  9. Australian Rheumatology Association. How To Use This Guideline. in An Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis https://app.magicapp.org/#/guideline/LqRV3n (2023).

Download references

Acknowledgements

K.H.C. is supported by the US National Institutes of Health (NIH K24 AR066109).

Author information

Authors and Affiliations

  1. Division of Clinical Immunology and Allergy, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands

    Jacob J. E. Koopman

  2. Division of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Jacob J. E. Koopman & Karen H. Costenbader

Authors
  1. Jacob J. E. Koopman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen H. Costenbader
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacob J. E. Koopman.

Ethics declarations

Competing interests

K.H.C. declares that she has received grants and/or research support from Amgen, AstraZeneca Exagen Diagnostics, Gilead, GlaxoSmithKline, and Janssen and has acted as a consultant for Amgen, Bristol-Myers Squibb, Cabaletta Bio, Eli Lilly, GlaxoSmithKlein and Janssen. J.J.E.K. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koopman, J.J.E., Costenbader, K.H. Shifting the SLE management paradigm: challenges and implications. Nat Rev Rheumatol 20, 5–6 (2024). https://doi.org/10.1038/s41584-023-01058-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-023-01058-5

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing